Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of azacitidine + valproic acid in myelodysplastic syndrome and other myeloid neoplasms not eligible for intensive chemotherapy
2005-004454-27Phase 2Completed
- Sponsor
- Heinrich Heine University Düsseldorf
- Start
- May 2006
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of azacitidine and valproic acid in myelodysplastic syndrome (MDS) and myeloid diseases, sponsored by Heinrich Heine University Düsseldorf. Primary endpoint: Safety and toxicity. Started May 2006; status: completed.
02
Drugs
azacitidinevalproic acid
03
Conditions
myelodysplastic syndrome (MDS)myeloid diseases
Beyond the preview
Go deeper on 2005-004454-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004454-27.